How Analysts Feel About Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)?

Investors sentiment decreased to 1.29 in 2018 Q3. Its down 0.21, from 1.5 in 2018Q2. It turned negative, as 19 investors sold Enanta Pharmaceuticals, Inc. shares while 54 reduced holdings. 36 funds opened positions while 58 raised stakes. 16.15 million shares or 10.28% more from 14.64 million shares in 2018Q2 were reported.
5,676 are held by Yorktown Rech Com. Prelude Cap Mgmt Limited Liability Corp stated it has 116 shares. Fincl Bank Of Mellon Corp has 256,446 shares. Barclays Public Limited, United Kingdom-based fund reported 28,533 shares. Quantbot Technologies Lp reported 1,170 shares. Wells Fargo & Communications Mn holds 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 24,055 shares. 10,849 are owned by Thrivent Fincl For Lutherans. Virginia Retirement System Et Al stated it has 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Profund Advsr Limited Liability Co holds 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) or 2,404 shares. Bancshares Of America De holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 7,507 shares. 7,391 are held by Element Mngmt Lc. Ny State Teachers Retirement Sys invested in 39,899 shares or 0.01% of the stock. Gp One Trading Lp has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Pnc Financial Services reported 385 shares stake. Connor Clark Lunn Invest Mngmt Limited invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Since July 18, 2018, it had 0 insider purchases, and 2 insider sales for $779,632 activity.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 2 analysts covering Enanta Pharmaceuticals (NASDAQ:ENTA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals had 2 analyst reports since August 8, 2018 according to SRatingsIntel. The rating was downgraded by Oppenheimer to “Perform” on Wednesday, August 8. Below is a list of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) latest ratings and price target changes.

13/12/2018 Broker: Berenberg Rating: Buy New Target: $80 Initiates Coverage On
08/08/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Perform Old Target: $135 Downgrade

The stock decreased 1.68% or $1.26 during the last trading session, reaching $73.8. About 165,679 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 56.90% since January 14, 2018 and is uptrending. It has outperformed by 56.90% the S&P500.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.43 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 21.21 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.